Qualigen Therapeutics Receives Nasdaq Listing Confirmation

Qualigen Therapeutics received two notices from Nasdaq Listing Qualifications office regarding its compliance with $2.5M stockholder's equity requirement. The company filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025, and successfully closed a $4.5M private placement of Series A-3 Preferred Stock to regain compliance. Nasdaq accepted the company's plan to maintain compliance with all applicable continued listing standards. Qualigen will continue to take necessary actions to maintain its Nasdaq listing.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has been navigating a compliance challenge with its Nasdaq listing status. The company received two communications from Nasdaq regarding its listing compliance issues. On July 23, 2025, Nasdaq informed Qualigen that it had failed to meet the $2.5 million stockholders' equity requirement based on its March 31 quarterly filing. This is a fundamental compliance metric for continued listing under Nasdaq Rule 5550(b)(1).

In response, Qualigen successfully addressed several key requirements. First, it filed its delayed Q1 2025 10-Q by the July 21 deadline. More importantly, Qualigen regained compliance with the equity requirement through a $4.5 million private placement of Series A-3 Preferred Stock that closed prior to the July 28 deadline. This capital raise is crucial as it provides the necessary financial cushion to meet the minimum stockholders' equity threshold. Additionally, Qualigen has submitted a sustainability plan to Nasdaq demonstrating how it intends to maintain compliance over the next 12 months.

While the company appears to have addressed the immediate compliance issues, management appropriately acknowledges that future compliance isn't guaranteed. The upcoming 8-K filing with a pro forma balance sheet will provide more concrete evidence of the company's restored compliance position. This situation highlights the financial constraints Qualigen has been operating under. The need for emergency capital raising to maintain listing requirements suggests underlying financial challenges that investors should monitor closely in upcoming quarters.

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The company's pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors. Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation. Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders.

For more information about Qualigen Therapeutics, Inc., please visit [www.qlgntx.com](http://www.qlgntx.com).

References:
[1] https://www.stocktitan.net/news/QLGN/qualigen-therapeutics-provides-update-on-nasdaq-communications-and-ldwaz2iamw0d.html
[2] https://www.marketscreener.com/news/qualigen-therapeutics-provides-update-on-nasdaq-communications-and-continued-listing-status-ce7c5fd8d08ff724